LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 380

Search options

  1. Article ; Online: FHBF: Federated hybrid boosted forests with dropout rates for supervised learning tasks across highly imbalanced clinical datasets.

    Pezoulas, Vasileios C / Kalatzis, Fanis / Exarchos, Themis P / Goules, Andreas / Tzioufas, Athanasios G / Fotiadis, Dimitrios I

    Patterns (New York, N.Y.)

    2024  Volume 5, Issue 1, Page(s) 100893

    Abstract: Although several studies have deployed gradient boosting trees (GBT) as a robust classifier for federated learning tasks (federated GBT [FGBT]), even with dropout rates (federated gradient boosting trees with dropout rate [FDART]), none of them have ... ...

    Abstract Although several studies have deployed gradient boosting trees (GBT) as a robust classifier for federated learning tasks (federated GBT [FGBT]), even with dropout rates (federated gradient boosting trees with dropout rate [FDART]), none of them have investigated the overfitting effects of FGBT across heterogeneous and highly imbalanced datasets within federated environments nor the effect of dropouts in the loss function. In this work, we present the federated hybrid boosted forests (FHBF) algorithm, which incorporates a hybrid weight update approach to overcome ill-posed problems that arise from overfitting effects during the training across highly imbalanced datasets in the cloud. Eight case studies were conducted to stress the performance of FHBF against existing algorithms toward the development of robust AI models for lymphoma development across 18 European federated databases. Our results highlight the robustness of FHBF, yielding an average loss of 0.527 compared with FGBT (0.611) and FDART (0.584) with increased classification performance (0.938 sensitivity, 0.732 specificity).
    Language English
    Publishing date 2024-01-12
    Publishing country United States
    Document type Journal Article
    ISSN 2666-3899
    ISSN (online) 2666-3899
    DOI 10.1016/j.patter.2023.100893
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Experimental models of Sjögren's syndrome: differences and similarities with human disease.

    Kaklamanos, Aimilios / Goules, Andreas V / Tzioufas, Athanasios G

    Clinical and experimental rheumatology

    2022  

    Abstract: Mouse models have been employed extensively to provide pathogenetic insights into many complex human disorders including systemic autoimmune diseases. The explosion of biotechnology and molecular biology have simplified the procedures to design and ... ...

    Abstract Mouse models have been employed extensively to provide pathogenetic insights into many complex human disorders including systemic autoimmune diseases. The explosion of biotechnology and molecular biology have simplified the procedures to design and generate mouse models with the phenotype of interest. In this line, more than 30 mouse models have been proposed or developed to resemble Sjögren's syndrome (SS) in humans, in an attempt to better understand the pathophysiology of the disease and design more effective treatments. So far, none of these models has been proven an ideal recapitulation of the human disease, although each model mimics particular aspects of the human SS counterpart. This review summarises the main characteristics of the mouse models of SS that have been developed hitherto, comparing them with the human SS in terms of clinical features, sex predilection, histopathology, autoantibodies production, and propensity for lymphoma. The interpretation of these experimental models with cautiousness and the realisation of the differences between human and mouse physiology and disease pathophysiology, may render mice a useful tool to study in depth SS and reveal new therapeutic perspectives.
    Language English
    Publishing date 2022-10-19
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    DOI 10.55563/clinexprheumatol/d4cx78
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Type-III interferons in Sjögren's syndrome.

    Apostolou, Eirini / Tzioufas, Athanasios G

    Clinical and experimental rheumatology

    2020  Volume 38 Suppl 126, Issue 4, Page(s) 245–252

    Abstract: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterised by aberrant activation of innate and adaptive immune responses. Part of this hyper-activation is due to the interferon (IFN) system. Deregulated expression and activity of ... ...

    Abstract Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterised by aberrant activation of innate and adaptive immune responses. Part of this hyper-activation is due to the interferon (IFN) system. Deregulated expression and activity of the type-I IFN system has been extensively studied in pSS. Type-III interferons (IFNs) are the latest addition to the IFN family, and exhibit potent anti-viral functions, similarly to type-I IFNs. More recently they have started to attract attention as key modulators in the interface of innate and adaptive immunity and chronic inflammation. Deregulated expression of type-III IFNs has been demonstrated in various autoimmune diseases over the last ten years. The scope of this review is to summarise recent findings regarding the biology of type-III IFNs in pSS. We highlight factors that regulate their induction, their downstream effects, their similarities and differences with type-I IFNs and their possible modes of action in Sjögren's syndrome. Finally, we discuss their potential benefits as targets for therapeutic intervention.
    MeSH term(s) Adaptive Immunity ; Antiviral Agents ; Autoimmune Diseases ; Humans ; Interferon Type I ; Sjogren's Syndrome/drug therapy
    Chemical Substances Antiviral Agents ; Interferon Type I
    Language English
    Publishing date 2020-09-02
    Publishing country Italy
    Document type Journal Article ; Review
    ZDB-ID 605886-3
    ISSN 1593-098X ; 0392-856X
    ISSN (online) 1593-098X
    ISSN 0392-856X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Interaction of Human Salivary Gland Epithelial Cells with B Lymphocytes: Implications in the Pathogenesis of Sjögren's Syndrome.

    Kapsogeorgou, Efstathia K / Tzioufas, Athanasios G

    Mediterranean journal of rheumatology

    2020  Volume 31, Issue 4, Page(s) 424–426

    Abstract: Sjögren's syndrome (SS) is characterized by the aberrant activation of B-cells in both the target organs of autoimmune responses, such as the exocrine glands and the periphery. Furthermore, SS is strongly associated with the development of B-cell non- ... ...

    Abstract Sjögren's syndrome (SS) is characterized by the aberrant activation of B-cells in both the target organs of autoimmune responses, such as the exocrine glands and the periphery. Furthermore, SS is strongly associated with the development of B-cell non-Hodgkin lymphomas, which are considered to result from chronic aberrant activation of B-cells. Disturbances of the minor salivary gland (MSG) infiltrating and peripheral B-cells subpopulations have been described in SS patients; however, the underlying mechanisms have not been uncovered. SG epithelial cells (SGECs) play a key role in the development and organization of MSG lymphocytic infiltrates in SS patients. SGECs are suitably equipped to mediate the recruitment, activation, and differentiation of immune cells in SS, including CD4+-T cells. B-cell activating factor (BAFF) secretion by SGECs suggests that they can also fruitfully interact with B-cells and mediate their activation, differentiation, and disturbed subpopulations in SS. The effect of SGECs in the activation and differentiation of naïve peripheral B-cells, as this attested by phenotypical flow cytometric and cytokine production analyses, is under investigation in the current proposal. This approach is expected to enlighten the mechanisms underlying the aberrant activation and differentiation of B cells in SS and the discovery of novel therapeutic targets for its reversal.
    Language English
    Publishing date 2020-12-28
    Publishing country Greece
    Document type Journal Article
    ZDB-ID 3019943-8
    ISSN 2529-198X ; 2459-3516
    ISSN (online) 2529-198X
    ISSN 2459-3516
    DOI 10.31138/mjr.31.4.424
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Cardio-Rheumatology: Two Collaborating Disciplines to Deal with the Enhanced Cardiovascular Risk in Autoimmune Rheumatic Diseases.

    Manolis, Antonis S / Tzioufas, Athanasios G

    Current vascular pharmacology

    2020  Volume 18, Issue 6, Page(s) 533–537

    Abstract: In Part 1 of this Thematic Issue entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of ... ...

    Abstract In Part 1 of this Thematic Issue entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", a panel of specialists and experts in cardiology, rheumatology, immunology and related fields discussed the cardiovascular complications of spondyloarthritides, rheumatoid arthritis, Sjogren's syndrome and vasculitides, as well as relevant cardiovascular issues related to non-biologic and biologic disease-modifying anti-rheumatic drugs (DMARDs), and provided their recommendations for prevention and management of these complications. In part 2 of this Thematic Issue, experts discuss the enhanced cardiovascular risk conferred by additional autoimmune rheumatic diseases (ARDs), including systemic lupus erythematosus, the antiphospholipid syndrome, psoriasis and psoriatic arthritis and juvenile idiopathic arthritis. These, and the previous articles, place inflammation as the key common link to explain the enhanced risk of cardiovascular complications in patients with ARDs. It follows that treatment should probably target inflammation. From all these contemporary reviews, the conclusion that is derived further supports the notion of the emerging field of Cardio- Rheumatology where physicians and experts from these two disciplines collaborate in risk stratification and optimization of preventive strategies and drug therapies in patients with ARDs.
    MeSH term(s) Animals ; Anti-Inflammatory Agents/therapeutic use ; Antirheumatic Agents/therapeutic use ; Autoimmune Diseases/diagnosis ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/epidemiology ; Autoimmune Diseases/immunology ; Cardiology ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/epidemiology ; Cardiovascular Diseases/immunology ; Cardiovascular Diseases/prevention & control ; Cooperative Behavior ; Heart Disease Risk Factors ; Humans ; Inflammation/diagnosis ; Inflammation/drug therapy ; Inflammation/epidemiology ; Inflammation/immunology ; Interdisciplinary Communication ; Patient Care Team ; Prognosis ; Protective Factors ; Rheumatic Diseases/diagnosis ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/epidemiology ; Rheumatic Diseases/immunology ; Rheumatology ; Risk Assessment ; Specialization
    Chemical Substances Anti-Inflammatory Agents ; Antirheumatic Agents
    Language English
    Publishing date 2020-07-21
    Publishing country United Arab Emirates
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 2192362-0
    ISSN 1875-6212 ; 1570-1611
    ISSN (online) 1875-6212
    ISSN 1570-1611
    DOI 10.2174/1570161118666200721145718
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Cardio-Rheumatology: Cardiovascular Complications in Systemic Autoimmune Rheumatic Diseases / Is Inflammation the Common Link and Target?

    Manolis, Antonis S / Tzioufas, Athanasios G

    Current vascular pharmacology

    2020  Volume 18, Issue 5, Page(s) 425–430

    Abstract: In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, ... ...

    Abstract In the current Thematic Issue of Current Vascular Pharmacology (CVP), entitled "Systemic Autoimmune Rheumatic Diseases and Cardiology", presented in two parts, Part 1 and Part 2, review articles are included from specialists in cardiology, rheumatology, immunology and related fields. These reviews discuss the cardiovascular complications of the main systemic Autoimmune Rheumatic Diseases (ARDs). For example, the underlying pathogenetic mechanisms, the role of cardiovascular imaging and recommendations for prevention and management. These articles place inflammation as the key process, linking cardiovascular complications with ARDs. From all these reviews, the conclusion is the need for collaboration between the disciplines of Rheumatology and Cardiology to establish the emerging field of Cardio- Rheumatology. This will aid to fine-tune risk stratification and optimize preventive strategies and pharmacological therapies for patients with ARDs.
    MeSH term(s) Animals ; Anti-Inflammatory Agents/therapeutic use ; Antirheumatic Agents/therapeutic use ; Autoimmune Diseases/complications ; Autoimmune Diseases/drug therapy ; Autoimmune Diseases/immunology ; Autoimmune Diseases/mortality ; Cardiovascular Diseases/etiology ; Cardiovascular Diseases/immunology ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/prevention & control ; Heart Disease Risk Factors ; Humans ; Inflammation/complications ; Inflammation/drug therapy ; Inflammation/immunology ; Inflammation/mortality ; Protective Factors ; Rheumatic Diseases/complications ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/immunology ; Rheumatic Diseases/mortality
    Chemical Substances Anti-Inflammatory Agents ; Antirheumatic Agents
    Language English
    Publishing date 2020-05-15
    Publishing country United Arab Emirates
    Document type Editorial ; Introductory Journal Article
    ZDB-ID 2192362-0
    ISSN 1875-6212 ; 1570-1611
    ISSN (online) 1875-6212
    ISSN 1570-1611
    DOI 10.2174/1570161118666200514222236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Book ; Conference proceedings: Proceedings of the Autoimmune Rheumatic Diseases Days

    Tzioufas, Athanasios G.

    Athens, June 24 - 26, 2004

    (Autoimmunity reviews ; 3, Suppl. 1)

    2004  

    Event/congress Autoimmune Rheumatic Disease Days (2004, Athen)
    Author's details ed. of the spec. ed.: Athanasios G. Tzioufas
    Series title Autoimmunity reviews ; 3, Suppl. 1
    Collection
    Language English
    Size S73 S. : Ill.
    Publisher Elsevier
    Publishing place Amsterdam
    Publishing country Netherlands
    Document type Book ; Conference proceedings
    HBZ-ID HT014226747
    Database Catalogue ZB MED Medicine, Health

    Kategorien

  8. Article ; Online: Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.

    Kaklamanos, Aimilios / Karamichalos, Panagiotis / Vlachoyiannopoulos, Panayiotis G / Tzioufas, Athanasios G

    Annals of the rheumatic diseases

    2021  Volume 82, Issue 6, Page(s) e134

    MeSH term(s) Humans ; COVID-19/complications ; Glucocorticoids/therapeutic use ; Cytokine Release Syndrome/drug therapy ; Cytokine Release Syndrome/etiology ; COVID-19 Drug Treatment ; Treatment Outcome
    Chemical Substances Glucocorticoids ; tocilizumab (I031V2H011)
    Language English
    Publishing date 2021-04-26
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2021-220411
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Epigenetic alterations in Sjögren's syndrome patient saliva.

    Karagianni, P / Goules, A V / Tzioufas, A G

    Clinical and experimental immunology

    2020  Volume 202, Issue 2, Page(s) 137–143

    Abstract: Epigenetic mechanisms have been implicated in the pathogenesis of Sjögren's syndrome (SS). Extensive alterations in DNA methylation have been described in minor salivary gland (MSG) epithelial cells and lymphocytes derived from SS patients compared to ... ...

    Abstract Epigenetic mechanisms have been implicated in the pathogenesis of Sjögren's syndrome (SS). Extensive alterations in DNA methylation have been described in minor salivary gland (MSG) epithelial cells and lymphocytes derived from SS patients compared to sicca controls. In an effort to identify novel potential epigenetic markers that could prove useful in diagnosis and disease monitoring, we explored whether DNA methylation differences can also be detected in saliva from SS patients compared to sicca controls. We performed DNA methylation analysis by methylation-sensitive restriction digestion followed by quantitative real-time polymerase chain reaction of selected genomic loci in saliva samples of 16 SS patients and 10 sicca controls with negative MSG biopsy. We identified reduced DNA methylation of the imprinting control region (ICR) of the H19 locus in SS patient saliva compared to sicca controls. Levels of saliva H19 ICR methylation were negatively correlated with C4 serum complement levels. Consistent with the reduced methylation of the ICR, H19 RNA levels were increased in SS patient peripheral blood mononuclear cells (PBMCs), while no significant change was observed in MSG H19 RNA levels compared to sicca controls. Our findings support that H19 ICR methylation could be a useful molecular epigenetic marker in monitoring patients with SS, highlighting saliva as a valuable biological sample in SS research and clinical practice. The role of H19 in SS pathogenesis remains to be addressed.
    MeSH term(s) Adult ; Aged ; Biomarkers/metabolism ; DNA Methylation ; Epigenesis, Genetic ; Female ; Genetic Loci ; Humans ; Male ; Middle Aged ; Saliva/metabolism ; Sjogren's Syndrome/genetics ; Sjogren's Syndrome/metabolism
    Chemical Substances Biomarkers
    Language English
    Publishing date 2020-07-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218531-3
    ISSN 1365-2249 ; 0009-9104 ; 0964-2536
    ISSN (online) 1365-2249
    ISSN 0009-9104 ; 0964-2536
    DOI 10.1111/cei.13492
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Helicobacter pylori

    Kalisperati, Polyxeni / Spanou, Evangelia / Pateras, Ioannis S / Evangelou, Konstantinos / Thymara, Irene / Korkolopoulou, Penelope / Kotsinas, Athanassios / Vlachoyiannopoulos, Panayiotis G / Tzioufas, Athanasios G / Kanellopoulos, Christos / Gorgoulis, Vassilis G / Sougioultzis, Stavros

    International journal of molecular sciences

    2024  Volume 25, Issue 7

    Abstract: Helicobacter pylori (H. pylori) ...

    Abstract Helicobacter pylori (H. pylori)
    MeSH term(s) Humans ; Helicobacter pylori ; Tumor Suppressor Protein p53/genetics ; Gastric Mucosa ; DNA Repair ; Epithelium
    Chemical Substances Tumor Suppressor Protein p53
    Language English
    Publishing date 2024-03-31
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms25073888
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top